Starpharma and Lilly sign new drug delivery collaboration

By Tim Dean
Monday, 01 February, 2010

Starpharma (ASX:SPL) announced today it has signed an agreement with U.S.-based Eli Lilly and Company, which will use Starpharma's dendrimer drug delivery technology in its human pharmaceutical line.

Dendrimers are synthetic molecules that can be built from the ground up to have specific chemical properties and can be used for the production of pharmaceuticals.

As a part of the agreement Lilly will fund a collaborative research and development programme with the aim of creating improved drugs using dendrimer technology, which will then be commercialised by Lilly.

Starpharma already has an agreement with Lilly, signed in May 2009, for the development of animal health products.

Starpharma (ASX:SPL) experienced a strong year in 2010, rising 231%, and is trading at 73c as of midday, up 2.8% for the day.

Related News

Quitting smoking increases life expectancy even for seniors

Although the benefits of quitting smoking diminish with age, there are still substantial gains...

Stem cell transplants treat blindness in mini pigs

Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...

Sugary drinks raise cardiovascular disease risk, but occasional sweets don't

Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd